Safety and Tolerability of Intravenous Immunoglobulin in Chronic Inflammatory Demyelinating Polyneuropathy: Results of the ProCID Study

Department of Neurology, Johns Hopkins University, Baltimore, MD, 21287, USA. Department of Neurology, Erasmus University Medical Center, 3015 CE, Rotterdam, The Netherlands. Department of Neurology, Medical Faculty, Heinrich Heine University, 40225, Düsseldorf, Germany. Brain and Mind Center, University of Sydney, Sydney, NSW, 2050, Australia. Department of Neurology, Medical University of Vienna, 1090, Vienna, Austria. Department of Neurology, Palacky University, 771 47, Olomouc, Czech Republic. Department of Neurology, Maastricht University Medical Center, 6229 HX, Maastricht, The Netherlands. Curaçao Medical Center, Willemstad, Curaçao. Department of Neurology, University of Toronto, Toronto, M5G 2C4, Canada. Octapharma PPG, 1100, Vienna, Austria.

Drug safety. 2023
BACKGROUND AND AIMS The ProCID study evaluated the efficacy and safety of three doses of a 10% liquid intravenous immunoglobulin (IVIg) preparation (panzyga(®)) in patients with chronic inflammatory demyelinating polyneuropathy (CIDP). This report describes the safety findings. METHODS Patients were randomised to receive a 2.0 g/kg induction dose followed by maintenance doses of either 0.5, 1.0 or 2.0 g/kg IVIg every 3 weeks over 24 weeks. RESULTS All 142 enrolled patients were included in the safety analyses. In total, 286 treatment-emergent adverse events (TEAEs) were reported in 89 patients, of which 173 (60.5%) were considered treatment-related. Most TEAEs were of mild severity. Eleven serious TEAEs were reported in 6 patients. Two serious TEAEs in one patient (headache and vomiting) were considered related to treatment, which resolved without study discontinuation. No treatment-related thrombotic events, haemolytic transfusion reactions or deaths occurred. One patient discontinued the study due to a TEAE (allergic dermatitis) probably related to IVIg. Headache was the only dose-dependent TEAE, with incidences ranging from 2.9 to 23.7%, the incidence of all other TEAEs was similar across treatment groups. Most TEAEs were associated with the induction dose infusion, and the rate of TEAEs decreased thereafter. The median (IQR) daily IVIg dose was 78 (64-90) g, and 94.4% of patients tolerated the maximal infusion rate of 0.12 ml/kg/min without pre-medication. INTERPRETATION Infusions of 10% IVIg at doses up to 2.0 g/kg with high infusion rates were safe and well tolerated in patients with CIDP. CLINICAL TRIAL NUMBERS EudraCT 2015-005443-14, NCT02638207.
Study details
Language : eng
Credits : Bibliographic data from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine